<DOC>
	<DOCNO>NCT00573417</DOCNO>
	<brief_summary>This pilot study eight-week , randomize , double-blind , placebo-controlled , escalate dose trial novel vigilance-promoting drug , modafinil , add stable dose clozapine 40 patient schizophrenia schizoaffective disorder . Modafinil initiate 100 mg/d . After 2 week , study drug may increase 200 mg/d 4 week , study drug may increase maximum 300 mg/d . Dose escalation base upon persistence sedation versus emergence side effect .</brief_summary>
	<brief_title>A Placebo-Controlled Trial Modafinil ( Provigil ) Added Clozapine Patients With Schizophrenia</brief_title>
	<detailed_description>This pilot study eight-week , randomize , double-blind , placebo-controlled , escalate dose trial novel vigilance-promoting drug , modafinil , add stable dose clozapine 40 patient schizophrenia schizoaffective disorder . Modafinil initiate 100 mg/d . After 2 week , study drug may increase 200 mg/d 4 week , study drug may increase maximum 300 mg/d . Dose escalation base upon persistence sedation versus emergence side effect . 1 . Evaluate tolerability safety modafinil compare placebo use SAFTEE vital sign . 2 . Evaluate effect size modafinil compare placebo upon wakefulness fatigue use Epworth Sleepiness Scale ( ESS ) Fatigue Severity Scale ( FSS ) . 3 . Evaluate effect size modafinil compare placebo upon negative symptom use SANS total score . 4 . Evaluate effect size modafinil compare placebo upon cognitive function use standard battery cognitive test . 5 . Evaluate effect size modafinil compare placebo upon weight , BMI , waist/hip circumference fast glucose lipid . 6 . Effect variability response placebo modafinil group outcome measure .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>Diagnosis Schizophrenia , subtype schizoaffective disorder Ages 1865 year Capable provide informed consent , capable provide assent guardian provide informed consent Stable dose clozapine least 1 month Three month stable psychotic symptom Serious medical neurological illness ( unstable cardiac disease , seizure disorder , malignancy , liver renal impairment , etc . ) Current substance abuse Pregnancy , nursing , unwilling use appropriate birth control measure participation female fertile . Unable complete neuropsychological test History serious blood dyscrasia require discontinuation clozapine Serious suicidal homicidal risk within past six month Current treatment psychostimulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Clozapine</keyword>
	<keyword>Cognition</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Negative Symptoms</keyword>
	<keyword>Wakefulness</keyword>
	<keyword>Fatigue</keyword>
</DOC>